Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2001-7-23
pubmed:abstractText
Over recent years, the use of antidepressants for the symptomatic treatment of insomnia has grown substantially, but controlled studies are still lacking. Our study is the first investigation to prove objective efficacy and tolerability of low doses of a sedating antidepressant in a randomized, double-blind, and placebo-controlled manner in patients with primary insomnia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0160-6689
pubmed:author
pubmed:issnType
Print
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
453-63
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11465523-Antidepressive Agents, Tricyclic, pubmed-meshheading:11465523-Chronic Disease, pubmed-meshheading:11465523-Dose-Response Relationship, Drug, pubmed-meshheading:11465523-Double-Blind Method, pubmed-meshheading:11465523-Doxepin, pubmed-meshheading:11465523-Drug Administration Schedule, pubmed-meshheading:11465523-Female, pubmed-meshheading:11465523-Health Status, pubmed-meshheading:11465523-Humans, pubmed-meshheading:11465523-Male, pubmed-meshheading:11465523-Middle Aged, pubmed-meshheading:11465523-Patient Dropouts, pubmed-meshheading:11465523-Placebos, pubmed-meshheading:11465523-Polysomnography, pubmed-meshheading:11465523-Psychiatric Status Rating Scales, pubmed-meshheading:11465523-Severity of Illness Index, pubmed-meshheading:11465523-Sleep, pubmed-meshheading:11465523-Sleep Initiation and Maintenance Disorders, pubmed-meshheading:11465523-Treatment Outcome
pubmed:year
2001
pubmed:articleTitle
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.
pubmed:affiliation
Department of Psychiatry and Psychotherapy, Georg-August-University of Göttingen, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't